Spinraza denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for spinraza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Issue a "Not FDA-Approved" Denial for Spinraza

This denial category for Spinraza (nusinersen) almost always reflects one of two situations: (1) an administrative or coding error in the prior authorization submission that caused the reviewer to misidentify the drug or indication, or (2) a policy interpretation that the specific use requested — such as a particular SMA type, age group, or clinical context — falls outside the FDA-approved labeling.

Spinraza has received FDA approval for SMA. If this denial was issued despite a submission for an on-label use, it may be reversible with minimal documentation simply by providing a copy of the FDA prescribing information and clarifying the clinical facts. If the use is genuinely off-label, the appeal requires a more robust clinical justification.

## Federal Appeal Rights

• ACA §2719 external review: Available for non-grandfathered plans. The external reviewer will independently assess whether the use is consistent with accepted medical practice, regardless of Aetna's initial classification. Window is approximately four months from denial.
• ERISA §503: Employer-plan members may request the specific basis for the denial — ask Aetna in writing to identify exactly which FDA-approval criterion was not met.
• Expedited review: Warranted given SMA's progressive nature. Request explicitly.

## Documentation to Gather

• FDA prescribing information: Attach the current, complete FDA-approved prescribing information for Spinraza. Highlight the specific approved indication and confirm the patient's diagnosis falls within it.
• Diagnosis confirmation: Genetic testing results and neuromuscular specialist diagnosis notes confirming the specific SMA type.
• Clarification of the requested use: A clear, concise statement from the prescriber confirming that the requested use is on-label, with reference to the FDA label language.
• If off-label use: A detailed letter from the treating specialist explaining the medical rationale, referencing applicable professional society guidance (without citing specific statistics), and documenting the absence of an FDA-approved alternative for the specific clinical scenario.
• Compendia references if applicable: For off-label use, certain recognized clinical compendia support coverage under Medicare and may be persuasive for commercial plans as well — your prescriber or pharmacist can identify relevant compendia citations.

## Criteria-Mapping Framework

Request Aetna's Clinical Policy Bulletin for Spinraza and identify exactly what FDA-approval criterion the denial relies on. Then:

| Denial Basis (per Aetna) | Rebuttal Evidence | |---|---| | Drug not FDA-approved for stated indication | FDA label (attached), confirmed indication | | Patient's specific condition not within approved label | Genetic report + SMA type documentation + specialist note | | [Any other stated basis] | [Specific response] |

If this denial appears to be an administrative error, note that in the appeal cover letter and request expedited correction before the formal appeal clock runs, to avoid unnecessary delay.